WideCells Group

News Releases

Published research note on WideCells Group plc

Shard Capital have published a research note on WideCells Group plc (WDC : LSE), the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment.

Corporate Charity Commitment

WideCells Group PLC (‘WideCells Group’ or ‘the Group’) Corporate Charity Commitment WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, is delighted to announce that it has finalised a corporate charity engagement plan as part of its active corporate social responsibility programme.  Reflecting his commitment to promoting medical development and health and well-being at both a corporate and personal level, the Group’s Chief Executive Office (‘CEO’) João Andrade has commenced training to participate in a 135 mile ultramarathon in the Californian desert in order to raise money for three primary charities: BigMoose, a non-profit organisation which aims to tackle homelessness by training homeless people as baristas, the Portuguese Association Multiple Sclerosis (‘SPEM’ – the Sociedade Portuguesa de Esclerose Múltipla) and CHAMPS Appeal, which helps children with Hirschsprung's Disease and bowel/bladder diversions.

INTERVIEW: WideCells Group PLC New Agreement in Brazil

INTERVIEW: WideCells Group PLC New Agreement in Brazil WideCells Group PLC (LON:WDC), the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, has today announced that its 100% owned subsidiary CellPlan Limited (‘CellPlan’) has signed a Definitive Agreement (‘the Agreement’) which will see its first-of-its-kind stem cell healthcare insurance plan and medical concierge service offered to both new and existing clients of Hemocord Clinica Medica Ltd (‘Hemocord’). Hemocord, which has been operating since 2004, is a world-class leader in cord blood storage, with facilities in Brazil. This is CellPlan’s second agreement with a cord blood storage facility and its first agreement in this geography, which represents a rapidly growing market. http://www.directorstalkinterviews.com/interview-widecells-group-plc-new-agreement-brazil/412731261

Proactive

WideCells signs deal to roll out CellPlan stem cell services to Hemocord Medica

WideCells signs deal to roll out CellPlan stem cell services to Hemocord Medica Ltd   WideCells expects the deal with the Brazilian cord blood storage facility to expand its customer base and boost revenues WideCells Group plc (LON:WDC) has signed a definitive agreement with Brazilian cord blood storage facility, Hemocord Clinica Medica Ltd, to supply its stem cell services. CellPlan Limited, a wholly-owned subsidiary of Widecells, will offer new and existing clients of Hemocord its stem cell healthcare insurance plan and medical concierge service. Hemocord currently stores about 5,000 stem cells, which WideCells said will boost CellPlan’s customer base and give the company exposure to the largest cord blood storage market in South America - estimated to be worth US$445mln by 2023. The CellPlan product has a reference price of £170 per year and it will generate an average of £50 from each sale, after disbursements, commissions and reinsurance costs. "The market for services relating to stem cells in Brazil is strong and growing rapidly, and as such we are delighted that CellPlan is on track to deliver revenues from this exciting jurisdiction,” said WideCells chief executive, Joao Andrade. “This agreement with one of Brazil's most established cord blood storage facilities represents CellPlan's second commercial contract and sees our first-of-its-kind healthcare plan enter a new geography, in line with our global ambitions. As a group, we have now forged two potential revenue streams in Brazil having also secured a stem cell storage facility in-country.” WideCells said talks are also currently progressing with a number of cord blood storage facilities across the globe, with a further two well advanced.   http://www.proactiveinvestors.co.uk/companies/news/180278/widecells-signs-deal-to-roll-out-cellplan-stem-cell-services-to-hemocord-medica-ltd-180278.html​  

WideCells Group PLC (‘WideCells Group’ or ‘the Company’) shortlisted for a prest

WideCells is delighted to be shortlisted in this year’s 2017 Biotech and Money Awards which will take place at Merchant Taylors Hall in London later this year.   Biotech and Money Assembly and Awards is a 250-person Gala Dinner where the UK’s funding, finance and investment successes in the sector over the last 12 months will be celebrated.

Disrupt 100

WideCells Group in the Top 100 Disrupt List

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is delighted to announce that it has been ranked as the 21st most disruptive company globally by DISRUPT 100.  

WideCells Expects Growth In 2017, IPO Costs Hit 2016 Profit

LONDON (Alliance News) - WideCells Group PLC Thursday said it expects a year of growth in 2017, as costs related to its listing last July hit its 2016 pretax profit.

Shareholders in WideCells in good position to benefit from stem cell advances

WideCells is aiming to be a major supporting player through its development of a stem cell storage business and, having only listed in London last July, its newsflow so far looks to be pointing the way

WideCells Group PLC “ideally positioned” to start generating revenues

In a statement accompanying the firm’s 2016 results, chief executive Joao Andrade said WideCells has made “significant progress in the commercialisation of our stem cell services"

WideCells Group

Widecells Group plc A cash generative, global proposition, all-star cast

Widecells Group plc (LON:WDC) CEO João Andrade talks to DirectorTalk about the company, how it plans to provide support advancements to the stem cell industry, the new laboratory in Manchester, the launch of CellPlan and João also explains why he has such a strong team on-board.

CellPlan logo

WideCells Group PLC Secures two LOIs for CellPlan

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is pleased to provide an update on the continued commercialisation of its 100% owned subsidiary CellPlan Limited (‘CellPlan’), which has developed the world's first stem cell healthcare insurance plan and medical concierge service.  Having recently secured a maiden definitive agreement with Biovault Technical Ltd, the UK's largest private human tissue storage facility (‘Biovault’), to roll-out CellPlan to Biovault’s significant customer base (see announcement dated 9 January 2017), the Company is delighted to have signed two further non-binding Letter of Intent ('LOI') agreements to support the continued roll-out of CellPlan globally.  The Company has also developed a new commercial CellPlan product, YOUR EXPERT CONSULTATION, further bolstering CellPlan’s innovative service offering and creating a new revenue opportunity.

Definitive Agreement to Roll Out CellPlan to Customers of Cord Blood Store

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is pleased to announce that, further to its announcement released on 7 November 2016, its 100% owned subsidiary CellPlan Limited (‘CellPlan’), which has developed the world's first stem cell healthcare insurance plan and medical concierge service, has cemented its agreement with Biovault Technical Ltd (‘Biovault’) via a definitive agreement, which covers an initial five-year term.

WideCells Group PLC Logo

Widecells in tie-up with Cali-based medical device group

"Stem cell specialist Widecells Group PLC (LON:WDC) has inked a letter of intent with a California-based medical device company that could be worth up to £100,000. Qigenix has agreed to pay the sum in three stages so it can use Widecell's Institute of Stem Cell Technology…"

BRR Media - Interview WideCells CEO Joao Andrade at 121 Tech Investor Event

Watch Joao Andrade’s interview with BRR Media at 121 Tech Investment Event

A Letter To Shareholders From Our CEO | 24.10.2016

A letter for our shareholders from our CEO Joao Andrade.

WideCells Group PLC Launches WideCells Brazil

Facility provides WideCells Group with unrivalled opportunity to penetrate the Brazilian cord blood banking market which is projected to be worth US$445 million by 2023, the largest in South America’s booming stem cell industry

WDC Admission to Trading and First Day of Dealings

WideCells Group, the health care services company focused on collecting and storing stem cells and providing ground breaking insurance for stem cell treatment, is pleased to announce...

Stem Cell Insurance Firm WideCells Floats, Autins Plans Listing (ALLIPO)

LONDON (Alliance News) - WideCells Group PLC was admitted to trading on the London Stock Exchange's Main Market Wednesday...

Denplan founder Dr. Marilyn Orcharton joins board of stem cell insurance plan

Dr. Marilyn Orcharton, the founder of Denplan, is helping to roll-out the world's first insurance plan for the global stem cell industry, CellPlan.

Denplan co-founder joins board of stem cell firm

WideCells Group, which is innovating the growing stem cells industry through the delivery of a stem cell insurance plan, has appointed the Co-Founder of Denplan, Dr. Marilyn Orcharton, as Non-Executive Director to its Board.

Unlocking the Future of Cord Blood Banking – Interview with Joao Andrade, CEO

Joao Andrade, who is leading the exciting development of WideCells Group, gives a glimpse into how the global stem cell services provider aims to revolutionise healthcare.

World’s first-of-its-kind insurance plan launched

World’s first-of-its-kind insurance plan launched to make stem cell treatment accessible and affordable

CellPlan Launch The World’s First Global Stem Cell Healthcare Plan

Next Generation Of Medical Insurance To Unlock Potential Of Umbilical Cord Blood Banking  

Shard Capital Research Report

Shard Capital initiate coverage on WideCells PLC with maiden research report

Holdings in Company

Miton Group’s 8.41% holding Confirmed Via Today’s Holdings in Company RNS

WideCells interview with Vox Markets

João Andrade Chief Executive Officer of newly listed widecells Group (WDC) explains the business model, which is based in cord blood banking and stem cell treatment.

Firms riding out the post-Brexit waves better than bigger rivals

The latest figures from Dealogic (cited in Financial News) suggest 25 European companies have put stock market listings on hold in the run-up to, or in the aftermath of, the UK’s Leave vote.  

WideCells offers a truly unique insurance policy

Being focused on small growth companies we are used to hearing about the latest developments in healthcare and biotechnology..

WideCells launching soon!

Companies have taken the plunge and launched initial public offerings (IPOs)...

Stem Cell company will list on the Market

by  Tara Cunningham,    business reporter    Julia Bradshaw    Jon Yeomans 

BRR Media talks with João Andrade

CEO speaks with BRR Media

LSE Share Talk with João Andrade

Ground breaking IPO on the London Stock Exchange. 

WideCells Group PLC 2016

WideCells Group PLC ('WideCells Group' or 'the Group') £2m Placing, Admission to Trading and First Day of Dealings

CellPlan Launch The World’s First Global Stem Cell Healthcare Plan.

Next Generation Of Medical Insurance To Unlock Potential Of Umbilical Cord Blood Banking

Events

WideCells Group goes PLC

The WideCells Group is now public on the London Stock Exchange 27th July 2016.

World Cord Blood Congress 2016

CellPlan today launched the creation of the world’s first global stem cell healthcare plan, at the World Cord Blood Congress Europe 17th May 2016.

Videos

INTERVIEW: Widecells Group plc A cash generative, global proposition, all-star cast

Widecells Group plc (LON:WDC) CEO João Andrade talks to DirectorTalk about the company, how it plans to provide support advancements to the stem cell industry, the new laboratory in Manchester, the launch of CellPlan and João also explains why he has such a strong team on-board. WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. The Directors believe that the use of cord blood stem cells for transplant will drive one of the next important phases in medicine and is therefore developing market leading products in complementary, strategic areas which are designed to take advantage of substantial market opportunities in one of the fastest growing segments in the healthcare industry. With this in mind, it has created three divisions: · CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process · WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Center to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising on stem cell storage. · WideAcademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.  

WideCells taps into 'very interesting' Brazilian cord blood bank market

''We've been looking at the Brazilian market since we floated back in July last year. We've identified two cord blood banks there that could have the potential to meet our stringent quality criteria for our CellPlan products - the world's first stem cell insurance plan''.

Widecells Group expects the firm’s stem cell insurance plan, CellPlan, to generate its first sales and revenue within a matter of months

Widecells Group (LON:WDC) chief executive João Andrade expects the firm’s stem cell insurance plan, CellPlan, to generate its first sales and revenues within a matter of months.

WideCells interview with Vox Markets

João Andrade Chief Executive Officer of newly listed widecells Group (WDC) explains the business model, which is based in cord blood banking and stem cell treatment by Justin Waite.

João Andrade interview with TipTV

New dawn in Stem Cell Healthcare - A day after listing on the London Stock Exchange's Main Market, interviewed by Zak Mir of TipTV Finance.  

WideCells on a mission to make stem cell therapy accessible and affordable

WideCells Group Plc (LON:WDC) chief executive Joao Andrade and non-executive director Marilyn Orcharton stopped by the Stocktube studio.

Interview with Prof. Peter Hollands

Interview with Prof. Peter Hollands, WideCELLS Chief Scientific Officer.

How Do Stem Cells Work?

Liz Bonnin investigates new stem-cell research that could change the face of organ transplant surgery.

A Stem Cell Story

What are stem cells, where do they come from, and what do we really know about them? An award-winning introduction to stem cell research.

What are stem cells? - Craig A. Kohn

Is personalized medicine for individual bodies in our future? Lesson by Craig A. Kohn.

WideCells supercharged to support growth plans

Joao Andrade, chief executive of WideCells Group PLC ( LON:WDC), talks Proactive through their £750,000 fundraise as the regenerative medicines specialist looks to further its penetration of the rapidly growing stem cell market.

WideCells raises £750,000 as it looks to further its penetration of growing stem cell market

The cash will be spent on its three divisions: CellPlan; WideCells; and WideAcademy

WideCells Group secures research licence from UK's Human Tissue Authority

The research licence paves the way to a collaboration with Qigenix, which is assessing the potential to activate stem cells using lasers